SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

September 27, 2010 08:20 ET

BIOLASE Announces Extensive Restructuring

Completes Reduction of Breakeven Point to Approximately $32 Million

IRVINE, CA--(Marketwire - September 27, 2010) -  BIOLASE Technology, Inc (NASDAQ: BLTI), the world's leading dental laser company, announced today that it has completed a corporate-wide reorganization that has achieved the goal of reducing, by approximately 30%, its total current sales breakeven level.

Federico Pignatelli, Chairman and CEO, commented, "This restructuring was performed rapidly, but also with great care. I am pleased to report that the cost reduction was achieved while keeping the company structure intact." 

Pignatelli continued, "In essence, what we eliminated was unnecessary and non-essential for BIOLASE to perform successfully and with efficiency. At the same time, we are continuing our critical innovation and new product development activities. As the technology leader in laser dentistry, it is paramount for us to keep our R&D efforts at their historical levels, and that is where they will remain. With that in mind, our R&D department has been minimally affected by this restructuring. As a consequence of the new business model, and the reduction in overall fixed costs, our current yearly sales breakeven level is now at approximately $32 million on an EBITDA cash basis. It therefore becomes highly likely that BIOLASE will be profitable in the fourth quarter of 2010 and beyond."

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at, Twitter at, and YouTube at

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti (investors) or Len Hall (media)
    Allen & Caron